Literature DB >> 15981028

Relationship between bone mineral density and urine level of NTx in rheumatoid arthritis.

Tohgo Nonaka1, Fumiaki Nishisaka, Kanji Fukuda, Satoshi Sohen, Chiaki Hamanishi.   

Abstract

We analyzed the relationship between the level of type-I collagen N-telopeptide (NTx) in urine (U-NTx) and bone mineral density (BMD) in patients with rheumatoid arthritis (RA). The subjects were 62 female patients with RA who had experienced the menopause 5 years or more before the study commenced, and who had not been treated for osteoporosis. The mean age of the subjects was 61.6 years and the mean disease duration was 13.3 years. They were classified for global functional status (classes I to IV), and then grouped based on the presence or absence of corticosteroid administration. Bone mineral density (BMD) and U-NTx levels were measured. In the presence of corticosteroid administration (CS group; n = 40), the mean level of U-NTx/creatinine (Cr) was 88.8 nM and the percent young adult mean (%YAM) for BMD was 71.2%. In the no corticosteroid (nCS group; n = 22), the values were 72.1 nM and 78.2%, respectively. The U-NTx/Cr value and %YAM were not significantly different between the CS group and the nCS group. A negative correlation was observed between the U-NTx/Cr value and %YAM in both groups (P = 0.005 and P = 0.0265). No significant difference was observed for the U-NTx/Cr value or %YAM between the CS and nCS groups, in any class. In the CS group, a positive correlation was observed between the U-NTx/Cr value and the total dose of corticosteroid (P = 0.001), and a negative correlation was observed between the %YAM and the total dose of corticosteroid (P = 0.003). These results suggested that preventive medical treatment for osteoporosis is required for RA patients in class III, irrespective of whether they have had corticosteroid administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15981028     DOI: 10.1007/s00774-004-0605-0

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  20 in total

1.  A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis.

Authors:  L Sinigaglia; A Nervetti; Q Mela; G Bianchi; A Del Puente; O Di Munno; B Frediani; F Cantatore; R Pellerito; S Bartolone; G La Montagna; S Adami
Journal:  J Rheumatol       Date:  2000-11       Impact factor: 4.666

2.  Resolved: Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis.

Authors:  D L Conn
Journal:  Arthritis Rheum       Date:  2001-10

3.  Therapeutic criteria in rheumatoid arthritis.

Authors:  O STEINBROCKER; C H TRAEGER; R C BATTERMAN
Journal:  J Am Med Assoc       Date:  1949-06-25

Review 4.  The science and therapy of glucocorticoid-induced bone loss.

Authors:  N E Lane; B Lukert
Journal:  Endocrinol Metab Clin North Am       Date:  1998-06       Impact factor: 4.741

Review 5.  Biochemical markers in the assessment of bone disease.

Authors:  D D Bikle
Journal:  Am J Med       Date:  1997-11       Impact factor: 4.965

6.  Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data.

Authors:  R Ramsey-Goldman; J E Dunn; C F Huang; D Dunlop; J E Rairie; S Fitzgerald; S Manzi
Journal:  Arthritis Rheum       Date:  1999-05

7.  Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma
Journal:  Ann Intern Med       Date:  2002-01-01       Impact factor: 25.391

8.  Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells.

Authors:  E Jimi; I Nakamura; L T Duong; T Ikebe; N Takahashi; G A Rodan; T Suda
Journal:  Exp Cell Res       Date:  1999-02-25       Impact factor: 3.905

Review 9.  Osteoporosis in rheumatoid arthritis.

Authors:  J Dequeker; K Maenaut; J Verwilghen; R Westhovens
Journal:  Clin Exp Rheumatol       Date:  1995 Sep-Oct       Impact factor: 4.473

10.  Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.

Authors:  K Kobayashi; N Takahashi; E Jimi; N Udagawa; M Takami; S Kotake; N Nakagawa; M Kinosaki; K Yamaguchi; N Shima; H Yasuda; T Morinaga; K Higashio; T J Martin; T Suda
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  1 in total

Review 1.  Osteoporosis Pathophysiology, Epidemiology, and Screening in Rheumatoid Arthritis.

Authors:  Giovanni Adami; Kenneth G Saag
Journal:  Curr Rheumatol Rep       Date:  2019-05-23       Impact factor: 4.592

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.